PPARA and diabetes mellitus: Lanifibranor (IVA337) is a moderately potent and a well‐balanced pan PPAR‐α agonist.95 A phase‐IIb NATIVE study is underway (NCT03008070), with a second recruiting type 2 diabetes mellitus patients with NAFLD (NCT03459079).